Ipilimumab

Options
mrs_blkjak
mrs_blkjak Member Posts: 103
in Kidney Cancer #1

I'm wondering if anyone knows anything about this drug as it pertains to kidney cancer. I was told there was a story about this on the news a few days ago in which there was a claim that it had cured someone of kidney cancer (in addition to very promising results with stage 4 melanoma!). I'm having a hard time finding a lot on the Internet about this. Is it FDA approved only for melanoma? Can you only get it for RCC through a clinical trial?

i appreciate any information!

Comments

  • Texas_wedge
    Texas_wedge Member Posts: 2,798
    #2
    Options
    There's discussion of this

    There's discussion of this trial at this thread

    Nivolumab/Ipilimumab Trial vs. Sutent

    http://csn.cancer.org/forum/142/search?body=ipilimumab&title=

    and here's an inspiring story of someone who's been on that trial for a year and a half so far and is cancer free:

    http://www.salon.com/2013/05/17/my_truly_remarkable_cancer_breakthrough/

     Just for clarity - nivolumab is the trial drug Fox is on  and ipilimumab is the already FDA-approved drug (for melanoma, trade name Yervoy) which they're trying out on other cancers, including RCC.  Both are huge molecule monoclonal antibody drugs manufactured by BMS (Bristol Myers Squibb) and Ono Pharmaceuticals.

    At the moment it is only available for RCC via trial [unless there's some way of getting it off-label?].

     

  • TerriNick
    TerriNick Member Posts: 43
    #3
    Options
    Texas_wedge said:

    There's discussion of this

    There's discussion of this trial at this thread

    Nivolumab/Ipilimumab Trial vs. Sutent

    http://csn.cancer.org/forum/142/search?body=ipilimumab&title=

    and here's an inspiring story of someone who's been on that trial for a year and a half so far and is cancer free:

    http://www.salon.com/2013/05/17/my_truly_remarkable_cancer_breakthrough/

     Just for clarity - nivolumab is the trial drug Fox is on  and ipilimumab is the already FDA-approved drug (for melanoma, trade name Yervoy) which they're trying out on other cancers, including RCC.  Both are huge molecule monoclonal antibody drugs manufactured by BMS (Bristol Myers Squibb) and Ono Pharmaceuticals.

    At the moment it is only available for RCC via trial [unless there's some way of getting it off-label?].

     

    Trials

    Don't know if you are aware that there are trials of the stuff that Fox is on taking place at Mount Vernon. I think it is open to people who have tried Sutent and Votrient and need something else. I don't want to get anyone's hopes up unnecessarily but as i had heard whispers about it I thought I should let you all know.

    This is what I saw online

     

    Phase 3 Study of Nivolumab (anti-PD1,BMS-936558) vs. Everoli

    postby Rose Woodward » Thu Feb 28, 2013 10:18 pm

    Just a quick update that the above long awaited study is opening next week.

    It is for patients with advanced RCC that have failed 1 or 2 lines of anti-VEGF therapy (so could be sunitinib or pazopanib then axitinib for areas in which there is access to axitinib) i.e. 2nd or 3rd line.

    Obviously this anti-PD1 drug is potentially a very exciting development and has generated a lot of interest amongst patients both here and internationally.

    Centres in the south of England are Royal Marsden Hospital, Mount Vernon and Cambridge.

     

    The link is...

     


  • foxhd
    foxhd Member Posts: 3,181 Member
    #4
    Options
    TerriNick said:

    Trials

    Don't know if you are aware that there are trials of the stuff that Fox is on taking place at Mount Vernon. I think it is open to people who have tried Sutent and Votrient and need something else. I don't want to get anyone's hopes up unnecessarily but as i had heard whispers about it I thought I should let you all know.

    This is what I saw online

     

    Phase 3 Study of Nivolumab (anti-PD1,BMS-936558) vs. Everoli

    postby Rose Woodward » Thu Feb 28, 2013 10:18 pm

    Just a quick update that the above long awaited study is opening next week.

    It is for patients with advanced RCC that have failed 1 or 2 lines of anti-VEGF therapy (so could be sunitinib or pazopanib then axitinib for areas in which there is access to axitinib) i.e. 2nd or 3rd line.

    Obviously this anti-PD1 drug is potentially a very exciting development and has generated a lot of interest amongst patients both here and internationally.

    Centres in the south of England are Royal Marsden Hospital, Mount Vernon and Cambridge.

     

    The link is...

     


    Keeps getting better

    Thanks for adding to the "good news" posts. Yes it is very exciting. I'm able to be alot less concerned about long term effects and future problems. They are going to find many ways to effectively use this drug for many people. It is all very exciting.

  • Blueraidermike
    Blueraidermike Member Posts: 25
    #5
    Options
    Get my first infusion on May 28th

    I in the trial that is Nivolumab and Ipiimumab combo, I go to BIDMC for my first treatment on Tuesday.    Excited to get to participate.   I will get infusions every 3 weeks for 4 cycles and then go to every two weeks for one year. 

  • alice124
    alice124 Member Posts: 896 Member
    #6
    Options
    Blueraidermike said:

    Get my first infusion on May 28th

    I in the trial that is Nivolumab and Ipiimumab combo, I go to BIDMC for my first treatment on Tuesday.    Excited to get to participate.   I will get infusions every 3 weeks for 4 cycles and then go to every two weeks for one year. 

    First infusion

    Promise us you'll keep us posted on your progress. It's an exciting trial and we'll be anxiously awaiting updates. YES!

Discussion Boards